Safety and pharmacodynamics of a single infusion of danavorexton in adults with obstructive sleep apnea experiencing excessive daytime sleepiness despite adequate use of CPAP
Source : https://www.sciencedirect.com/science/article/abs/pii/S1389945723001703?via=ihub
Sleep disruption can significantly affect patients with obstructive sleep apnea. * Excessive daytime sleepiness can persist despite adequate CPAP use. * Improvements in key sleepiness measures were observed with danavorexton...
Highlights: Sleep disruption can significantly affect patients with obstructive sleep apnea. Excessive daytime sleepiness can persist despite adequate CPAP use. Improvements in key sleepiness measures were observed with danavorexton vs placebo.
Post-COVID Quality of Life and Sleep Among Younger Healthcare Workers of Designated COVID Care Centers: A Cross-Sectional Study
Introduction Frontline healthcare workers (FLHCWs) have been persuaded to work this coronavirus disease (COVID) pandemic way in and out but the pandemic has not subsided. The persistence of symptoms after...
Conclusions/Relevance: The present study has shown that even after the COVID vaccination doses received by the HCWs, sleep and Qol have still been impaired among infected younger healthcare staff. Acceptable and righteous efforts must be made by the institutions for proper policymaking to manage such infectious outbreaks in the future.
The metabolism of the dual orexin receptor antagonist daridorexant - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36809238/
Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia disorder and has shown improvement in sleep outcomes and daytime functioning. The present work describes its biotransformation...
Relevance: Daridorexant has three major metabolites which are well covered in these preclinical safety species. All of them retain some residual affinity towards orexin receptors. However, none of these is considered to contribute to the pharmacological effect of daridorexant as their active concentrations in the human brain are too...
Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis
Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1175372/full
Background: Systematic comparisons of the doses of the Food and Drug Administration (FDA)-approved dual orexin receptor antagonists (DORAs) for people with insomnia are limited.Methods: PubMed, Embase, Cochrane Library, and Clinicaltrials....
Conclusion: Suvorexant 20 mg, lemborexant 5 mg, lemborexant 10 mg, and daridorexant 50 mg represent suitable approaches for insomnia.
Effect of aging and a dual orexin receptor antagonist on sleep architecture and NREM oscillations including a REM Behavior Disorder phenotype in the PS19 mouse model of tauopathy
Source : https://www.jneurosci.org/content/early/2023/05/22/JNEUROSCI.1828-22.2023
The impact of tau pathology on sleep microarchitecture features, including slow oscillations, spindles, and their coupling has been understudied, in spite of the proposed importance of these electrophysiological features toward...
Significance Statement: The specific effect of tauopathy on sleep macro- and microarchitecture throughout aging remains unknown. Our key findings include: 1) the identification of a sleep EEG signature constituting an early biomarker of impending tauopathy, 2) sleep physiology deteriorates with aging that are also markers of offline cognitive...